COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00736528
Recruitment Status : Terminated (See Detailed Description for termination reason.)
First Posted : August 18, 2008
Last Update Posted : February 25, 2009
Information provided by:

Brief Summary:
To describe the safety, tolerability and pharmacokinetics of PF-04447943 after administration of multiple, ascending, oral doses to healthy elderly subjects.

Condition or disease Intervention/treatment Phase
Healthy Elderly Drug: PF-04447943 Drug: Placebo Phase 1

Detailed Description:

Additional Study Purpose Details: Phase I safety and pharmacokinetics study.

Detailed Description:

The study was terminated on 11/12/2008. There were no safety findings in this trial that resulted in the decision to terminate the trial. The study was closed in order to change the amount of drug that subjects would take and to shorten the number of days that the drug would be taken in a new study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Official Title: An Investigator And Subject-Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Doses Of PF-04447943 In Healthy Elderly Subjects
Study Start Date : August 2008
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2008

Arm Intervention/treatment
Experimental: PF-04447943 05 mg dose Drug: PF-04447943
05 mg BID for 14 days

Experimental: PF-04447943 15 mg dose Drug: PF-04447943
15 mg BID for 14 days

Experimental: PF-04447943 45 mg dose Drug: PF-04447943
45mg BID for 14 days

Placebo Comparator: Placebo Drug: Placebo
Placebo for 14 days

Primary Outcome Measures :
  1. Primary Safety: Adverse events, change from baseline in vital signs, triplicate ECG, clinical safety laboratory endpoints [ Time Frame: 14 days ]
  2. Pharmacokinetic endpoints will include plasma PF 04447943 AUCt, Cmax and Tmax [ Time Frame: 14 days ]

Secondary Outcome Measures :
  1. Changes in cognition from baseline [ Time Frame: 14 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years to 85 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy
  • Elderly
  • 65-85

Exclusion Criteria:

  • Evidence or history of clinically significant unstable disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00736528

Layout table for location information
United States, Florida
Pfizer Investigational Site
Gainesville, Florida, United States, 32608
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00736528    
Other Study ID Numbers: B0401002
First Posted: August 18, 2008    Key Record Dates
Last Update Posted: February 25, 2009
Last Verified: February 2009
Keywords provided by Pfizer:
safety, tolerability, pharmacokinetics, cognition